Adverse events and quadrivalent human papillomavirus recombinant vaccine

JAMA

Volumn 302, Issue 24, 2009, Pages 2657-

  Debold, Vicky ^a   Hurwitz, Eric ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGICAL DATA; GOVERNMENT; GUILLAIN BARRE SYNDROME; HUMAN; LETTER; NONHUMAN; PHYSICIAN; PRIORITY JOURNAL; SYSTEMATIC ERROR; VACCINATION; EPIDEMIOLOGY; FEMALE; METHODOLOGY; NOTE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIAS (EPIDEMIOLOGY); FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; RESEARCH DESIGN;

EID: 73949153275     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1880     Document Type: Letter

References (5)

1. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-757.
2. Gardasil vaccine safety: information from FDA and CDC on the safety of Gardasil vaccine. US Food and Drug Administration Web site. http://www.fda.gov /BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm179549.htm. Accessed August 23, 2009.
3. Legido A, Tenembaum SN, Katsetos CD, Menkes JH. Autoimmune and postinfectious diseases. In: Menkes JH, Sarnat HB, Maria BL, eds. Child Neurology. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005:601.
4. Rosenthal S, Chen B. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85(12):1706-1709.
5. Rothman KJ, Greenland S, Poole C, Lash TL. Causation and causal inference. In: Rothman KJ, Greenland S, Poole C, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:5-31.